Trials / Completed
CompletedNCT02912845
Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Kamada, Ltd. · Industry
- Sex
- All
- Age
- 0 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KamRAB - HRIG | wound infiltration or IM injection |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2019-11-13
- Completion
- 2019-11-13
- First posted
- 2016-09-23
- Last updated
- 2021-09-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02912845. Inclusion in this directory is not an endorsement.